Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions
暂无分享,去创建一个
Rostyslav V Bubnov | L. Lazarenko | Olena E Nikitina | E. Nikitin | O. Demchenko | Galyna V Kovtonyuk | L. O. Ganova | V. O. Shevchuk | N. M. Nastradina | V. V. Bila | M. Spivak | Natalia M Nastradina
[1] A. Meisels,et al. Condylomatous lesions of the cervix and vagina. I. Cytologic patterns. , 1976, Acta cytologica.
[2] H. Hausen. HUMAN GENITAL CANCER: SYNERGISM BETWEEN TWO VIRUS INFECTIONS OR SYNERGISM BETWEEN A VIRUS INFECTION AND INITIATING EVENTS? , 1982, The Lancet.
[3] H. zur Hausen. Human genital cancer: synergism between two virus infections or synergism between a virus infection and initiating events? , 1982, Lancet.
[4] R Reid,et al. Genital warts and cervical cancer. IV. A colposcopic index for differentiating subclinical papillomaviral infection from cervical intraepithelial neoplasia. , 1984, American journal of obstetrics and gynecology.
[5] S. T. Traweek,et al. The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. , 1991, American journal of clinical pathology.
[6] Atypical hyperplasia and other abnormalities of prostatic epithelium. , 1993, Human pathology.
[7] C. Woodworth,et al. Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[8] P. Stern. Immunity to human papillomavirus-associated cervical neoplasia. , 1996, Advances in cancer research.
[9] Y. Hara,et al. Effect of herpes simplex virus on the DNA of human papillomavirus 18 , 1997, Journal of medical virology.
[10] L. Cole,et al. Immunoassay of human chorionic gonadotropin, its free subunits, and metabolites. , 1997, Clinical chemistry.
[11] C. Woodworth,et al. Relationship of stable integration of herpes simplex virus‐2 BglII N subfragmentXho2 to malignant transformation of human papillomavirus‐immortalized cervical keratinocytes , 1998, International journal of cancer.
[12] T. Kiyono,et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells , 1998, Nature.
[13] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[14] L. Brinton,et al. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[15] A. Van Daele,et al. Angiogenesis in cervical intraepithelial neoplasia and the risk of recurrence. , 1999, American journal of obstetrics and gynecology.
[16] P. Cristoforoni,et al. Effects of Human Papillomavirus‐Associated Cells on Human Immunodeficiency Virus Gene Expression , 2000, Obstetrics and gynecology.
[17] Harald zur Hausen,et al. Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in Carcinogenesis , 2000 .
[18] E. Hawk,et al. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[19] J. McDougall,et al. Small Tumor Virus Genomes Are Integrated near Nuclear Matrix Attachment Regions in Transformed Cells , 2001, Journal of Virology.
[20] J. Cuzick,et al. The effect of stopping smoking on cervical Langerhans'cells and lymphocytes , 2001, BJOG : an international journal of obstetrics and gynaecology.
[21] Human papillomavirus-16-E7 oncoprotein enhances the expression of adhesion molecules in cervical endothelial cells but not in human umbilical vein endothelial cells. , 2001, Journal of human virology.
[22] D. Zimonjic,et al. Chromosome‐mediated alterations of the MYC gene in human cancer , 2002, Journal of cellular and molecular medicine.
[23] S. Franceschi,et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. , 2002, Journal of the National Cancer Institute.
[24] W. McCluggage,et al. Recent advances in immunohistochemistry in gynaecological pathology , 2002, Histopathology.
[25] M. Bryś,et al. Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium. , 2002, Cancer letters.
[26] A. Degener,et al. Involvement of Herpes Simplex Virus Type 2 in Modulation of Gene Expression of Human Papillomavirus Type 18 , 2002, International journal of immunopathology and pharmacology.
[27] J. Nelson,et al. The endothelin axis: emerging role in cancer , 2003, Nature Reviews Cancer.
[28] Eileen M. Burd,et al. Human Papillomavirus and Cervical Cancer , 1988, The Lancet.
[29] S. Vieira,et al. Quantification of angiogenesis in cervical cancer: a comparison among three endothelial cell markers. , 2004, Gynecologic oncology.
[30] J. M. van der Hulst,et al. Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 , 2004, Cancer Research.
[31] A. Malpica,et al. Depressed Type 1 Cytokine Synthesis by Superantigen-Activated CD4+ T Cells of Women with Human Papillomavirus-Related High-Grade Squamous Intraepithelial Lesions , 2004, Clinical Diagnostic Laboratory Immunology.
[32] N. McMillan,et al. A novel method for screening viral interferon-resistance genes. , 2004, Journal of Interferon and Cytokine Research.
[33] Rebecca Richards-Kortum,et al. Fluorescent nanocrystals for use in early cervical cancer detection. , 2005, Gynecologic oncology.
[34] B. King,et al. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer , 2005, Journal of Clinical Pathology.
[35] C. Meijer,et al. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions , 2005, Journal of Clinical Pathology.
[36] Xianhe Xie,et al. Proteomic analysis of progressive factors in uterine cervical cancer , 2005, Proteomics.
[37] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[38] A. Scaloni,et al. Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. , 2005, Mass spectrometry reviews.
[39] W. Günzburg,et al. Viruses and human breast cancer. , 2006, Future microbiology.
[40] P. Gariglio,et al. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. , 2006, Viral immunology.
[41] Jong-Sup Park,et al. Role of proteomics in translational research in cervical cancer , 2006, Expert review of proteomics.
[42] M. Stanley. Immune responses to human papillomavirus. , 2006, Vaccine.
[43] G. Geiss,et al. Discovery of Novel Methylation Biomarkers in Cervical Carcinoma by Global Demethylation and Microarray Analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.
[44] Y. Kuramitsu,et al. Proteomic analysis of cancer tissues: Shedding light on carcinogenesis and possible biomarkers , 2006, Proteomics.
[45] K. Ault. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials , 2007, The Lancet.
[46] Peter J. F. Snijders,et al. Cytokine Release in HR-HPV(+) Women without and with Cervical Dysplasia (CIN II and III) or Carcinoma, Compared with HR-HPV(−) Controls , 2007, Mediators of inflammation.
[47] E. Cambruzzi,et al. Herpes simplex virus type 2 and Chlamydia trachomatis in adenocarcinoma of the uterine cervix. , 2007, Gynecologic oncology.
[48] Ole Gemeinhardt,et al. Real-time sonoelastography of the cervix: tissue elasticity of the normal and abnormal cervix. , 2007, Academic radiology.
[49] S. Franceschi,et al. Human papillomavirus and HPV vaccines: a review. , 2007, Bulletin of the World Health Organization.
[50] Da‐hong Wang,et al. Biomarkers of oxidative/nitrosative stress: an approach to disease prevention. , 2007, Acta medica Okayama.
[51] Gun-Hee Kim,et al. Biomarkers for oxidative stress status of DNA, lipids, and proteins in vitro and in vivo cancer research. , 2007, Toxicology.
[52] Mithat Gönen,et al. Screening for cancer with PET and PET/CT: potential and limitations. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[53] D. Spandidos,et al. Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. , 2007, International journal of oncology.
[54] Y. Hiraku,et al. Nitrative and oxidative DNA damage in cervical intraepithelial neoplasia associated with human papilloma virus infection , 2007, Cancer science.
[55] Ivan M. Melnik. Genetic Algorithm for Solving the Problem of an Optimum Regression Model Construction as a Discrete Optimization Problem , 2008 .
[56] J. Lesnock,et al. Cervical cancer screening in pregnancy. , 2008, Obstetrics and gynecology clinics of North America.
[57] S. Tsao,et al. Transforming growth factor beta1 promotes chromosomal instability in human papillomavirus 16 E6E7-infected cervical epithelial cells. , 2008, Cancer research.
[58] X. Van Ostade,et al. Comprehensive proteomic analysis of human cervical-vaginal fluid using colposcopy samples , 2009, Proteome Science.
[59] G. Boulet,et al. Human Papillomavirus in Cervical Cancer Screening: Important Role as Biomarker , 2008, Cancer Epidemiology Biomarkers & Prevention.
[60] A. Gadducci,et al. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. , 2008, Critical reviews in oncology/hematology.
[61] S. Goldie,et al. The economic burden of noncervical human papillomavirus disease in the United States. , 2008, American journal of obstetrics and gynecology.
[62] Discussion: ‘Perinatal consequences of fetal macrosomia’ by Zhang et al , 2008 .
[63] E. Myers. The economic impact of HPV vaccines: not just cervical cancer. , 2008, American journal of obstetrics and gynecology.
[64] M. Stanley. Immune responses to human papilloma viruses. , 2009, The Indian journal of medical research.
[65] E. Korobowicz,et al. Prevalence of Chlamydia trachomatis and herpes simplex virus 2 in cervical carcinoma associated with human papillomavirus detected in paraffin-sectioned samples. , 2009, European journal of gynaecological oncology.
[66] A. Botezatu,et al. TGF-beta signalling pathway factors in HPV-induced cervical lesions. , 2010, Roumanian archives of microbiology and immunology.
[67] J. Machac,et al. PET/CT evaluation of cervical cancer: spectrum of disease. , 2010, Radiographics : a review publication of the Radiological Society of North America, Inc.
[68] H. Schild,et al. Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures , 2010, EPMA Journal.
[69] J. Flammer,et al. Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs , 2010, EPMA Journal.
[70] N. deSouza,et al. Evaluation of magnetic resonance diffusion and spectroscopy measurements as predictive biomarkers in stage 1 cervical cancer. , 2010, Gynecologic oncology.
[71] Michael House,et al. A study of the anisotropy and tension/compression behavior of human cervical tissue. , 2010, Journal of biomechanical engineering.
[72] Ting Wang,et al. The role of human papillomavirus infection in breast cancer , 2012, Medical Oncology.
[73] A. Jemal,et al. Global Cancer Statistics , 2011 .
[74] Niva Shapira,et al. Women's higher health risks in the obesogenic environment: a gender nutrition approach to metabolic dimorphism with predictive, preventive, and personalised medicine , 2013, EPMA Journal.
[75] G. Anton,et al. Investigation of Th1/Th2 cytokine profiles in patients with laryngo-pharyngeal, HPV-positive cancers , 2013, European Archives of Oto-Rhino-Laryngology.
[76] L. Rocha-Zavaleta,et al. Peripheral blood lymphocytes from low-grade squamous intraepithelial lesions patients recognize vaccine antigens in the presence of activated dendritic cells, and produced high levels of CD8 + IFNγ + T cells and low levels of IL-2 when induced to proliferate , 2012, Infectious Agents and Cancer.
[77] U. Lushchyk,et al. Predictive and preventive strategies to advance the treatments of cardiovascular and cerebrovascular diseases: the Ukrainian context , 2012, EPMA Journal.
[78] N. Kiviat,et al. Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. , 2012, Gynecologic oncology.
[79] R. Rajkumar. Topics on Cervical Cancer With an Advocacy for Prevention , 2012 .
[80] Youyun Zhao,et al. Relationship between cervical disease and infection with human papillomavirus types 16 and 18, and herpes simplex virus 1 and 2 , 2012, Journal of medical virology.
[81] M. Serrano,et al. New Biomarkers for Cervical Cancer – Perspectives from the IGF System , 2012 .
[82] H. Schild,et al. Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? , 2013, EPMA Journal.
[83] A. Verma,et al. Evaluation of diffusion-weighted imaging as a predictive marker for tumor response in patients undergoing chemoradiation for postoperative recurrences of cervical cancer. , 2012, Journal of cancer research and therapeutics.
[84] CHOICE OF DIAGNOSTIC DECISION MAKING IN MEDICINE AND INTERVENTION MISTAKE PREDICTION USING MATHEMATICAL MODELS , 2012 .
[85] O. Golubnitschaja,et al. General Report & Recommendations in Predictive, Preventive and Personalised Medicine 2012: White Paper of the European Association for Predictive, Preventive and Personalised Medicine , 2012, EPMA Journal.
[86] A. Feigl,et al. The Global Economic Burden of Noncommunicable Diseases , 2012 .
[87] S. Mesogitis,et al. Three‐dimensional power Doppler ultrasound for the study of cervical cancer and precancerous lesions , 2012, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[88] Rostyslav V Bubnov. Evidence-based pain management: is the concept of integrative medicine applicable? , 2012, EPMA Journal.
[89] Rostyslav V Bubnov,et al. Gold nanoparticles - the theranostic challenge for PPPM: nanocardiology application , 2013, EPMA Journal.
[90] D. Theodorescu,et al. Secreted Protein Acidic and Rich in Cysteine (Sparc) in Cancer , 2013 .
[91] H. Schild,et al. ‘Suspect molecular signature’ in blood as the indicator of undiagnosed breast cancer, cancer risk and targeted prevention , 2013, EPMA Journal.
[92] Hong-wei Wang,et al. Increased expression of programmed death (PD)‐1 and its ligand PD‐L1 correlates with impaired cell‐mediated immunity in high‐risk human papillomavirus‐related cervical intraepithelial neoplasia , 2013, Immunology.
[93] Rostyslav V Bubnov,et al. Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology , 2013, EPMA Journal.
[94] Rostyslav V Bubnov,et al. Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age , 2013, EPMA Journal.
[95] Wen-lin Yang,et al. Mechanistic investigation of immunosuppression in patients with condyloma acuminata. , 2013, Molecular medicine reports.
[96] F. De Marco. Oxidative Stress and HPV Carcinogenesis , 2013, Viruses.
[97] John O. Prior,et al. The role of PET/CT in cervical cancer , 2013, Front. Oncol..
[98] F. Di Domenico,et al. Proteomics strategies to analyze HPV-transformed cells: relevance to cervical cancer , 2013, Expert review of proteomics.